Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397345 · ClinicalTrials.gov registry record · Phase 3
TroVax Renal Immunotherapy Survival Trial
A Phase 3 study of Clear Cell Renal Carcinoma, sponsored by Oxford BioMedica.
- Completed
- Registry status
- Phase 3
- Development phase
- 733
- Enrollment target
- 20
- Study locations
NCT00397345: Completed Phase 3 study of Clear Cell Renal Carcinoma, sponsored by Oxford BioMedica.
NCT00397345 is a Phase 3 study of Clear Cell Renal Carcinoma that has completed, run by Oxford BioMedica. The registered enrollment target is 733 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397345, a Phase 3 study of Clear Cell Renal Carcinoma, has completed, sponsored by Oxford BioMedica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 733 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Trovax
- BIOLOGICAL Standard of care therapy
Study Locations (20)
California
- La Jolla, CA - La Jolla
- The Angeles Clinic and Reseach Institute - Los Angeles
- 1300 N. Vermont Ave - Los Angeles
- UCLA Urology/Oncology - Los Angeles
- Scripps Cancer Center - San Diego
- Sharp Health Care - San Diego
Florida
- Broward Oncology Associates - Fort Lauderdale
- SCORE Physician Alliance - St. Petersburg
- SCORE Physician Alliance - St. Petersburg
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Georgia
- Augusta Oncology Associates - Augusta
- SMO-USA Inc. - Canton
Illinois
- Patricia A. Joyce Cancer Institute - Olympia Fields
- Edward H Kaplan and Associates - Skokie
Arizona
- AZ Cancer Center - Tucson
Arkansas
- Little Rock Hematology / Oncology Associates, P.A. - Little Rock
Colorado
- UCHSC - Aurora
District of Columbia
- Washington Cancer Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
What the finished NCT00397345 record still lists
NCT00397345 is an interventional study that assigns participants to a tested intervention. The registered 733 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Clear Cell Renal Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00397345 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00397345 about?
NCT00397345 is a clinical study titled "TroVax Renal Immunotherapy Survival Trial". The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
What is the current status of trial NCT00397345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 733 participants. The study started on 2006-09. Estimated completion is 2009-12.
What conditions does trial NCT00397345 study?
This clinical trial studies the following conditions: Clear Cell Renal Carcinoma.
What interventions are being tested in trial NCT00397345?
The interventions under investigation include: Placebo (BIOLOGICAL), Trovax (BIOLOGICAL), Standard of care therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00397345?
This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397345 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00397345's enrollment target sits among peer trials
733 484th of 2000 higher than 1,516 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia